Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment: James Berry, MD, MPH

NeurologyLive

April 25, 2023

Novel MS Drug Good as Gold in Phase II Study

Medpagetoday

April 25, 2023

ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein

Biopharma Dive

March 27, 2023

CNM-Au8 found to delay clinical worsening in ALS HEALEY trial

ALS News Today

March 10, 2023

ALS Advances and Hot Topics for MDA 2023: Matthew B. Harms, MD

NeurologyLive

March 9, 2023

CNM-Au8 Demonstrates Significant Survival Benefit in HEALEY-ALS Interim Analysis

NeurologyLive

March 9, 2023

Clene's Nanocrystal ALS treatment bounces back with positive data

BioSpace

March 9, 2023

MS New Notes: Briumvi, vitamin D, CNM-Au8

Multiple Sclerosis News Today

March 6, 2023

ACTRIMS 2023 – Michael Hotchkin, Chief Development Officer, Clene Inc.

Multiple Sclerosis News Today

February 27, 2023

CNM-Au8 Shows Positive Findings on MS-Related Biomarkers of Whole Brain, White Matter

NeurologyLive

February 14, 2023

Pagination

Current page 1
Page 2
Next page
Last page

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved